CA2926976C - Stable polypeptides binding to human complement c5 - Google Patents

Stable polypeptides binding to human complement c5 Download PDF

Info

Publication number
CA2926976C
CA2926976C CA2926976A CA2926976A CA2926976C CA 2926976 C CA2926976 C CA 2926976C CA 2926976 A CA2926976 A CA 2926976A CA 2926976 A CA2926976 A CA 2926976A CA 2926976 C CA2926976 C CA 2926976C
Authority
CA
Canada
Prior art keywords
seq
polypeptide
binding
compound
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2926976A
Other languages
English (en)
French (fr)
Other versions
CA2926976A1 (en
Inventor
Joakim Nilsson
Erik Nordling
Patrik Stromberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IPC Research LLC
Original Assignee
IPC Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IPC Research LLC filed Critical IPC Research LLC
Publication of CA2926976A1 publication Critical patent/CA2926976A1/en
Application granted granted Critical
Publication of CA2926976C publication Critical patent/CA2926976C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
CA2926976A 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5 Active CA2926976C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350986-4 2013-08-28
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
CA2926976A1 CA2926976A1 (en) 2015-03-05
CA2926976C true CA2926976C (en) 2023-11-28

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2926976A Active CA2926976C (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Country Status (29)

Country Link
US (1) US9994626B2 (enExample)
EP (2) EP3811961B1 (enExample)
JP (2) JP6767865B2 (enExample)
KR (1) KR102446636B1 (enExample)
CN (1) CN105658228B (enExample)
AU (1) AU2014314222B2 (enExample)
BR (1) BR112016003142A2 (enExample)
CA (1) CA2926976C (enExample)
CY (1) CY1123732T1 (enExample)
DK (1) DK3038633T3 (enExample)
ES (1) ES2842105T3 (enExample)
HR (1) HRP20210013T1 (enExample)
HU (1) HUE052613T2 (enExample)
IL (1) IL244218A (enExample)
LT (1) LT3038633T (enExample)
MX (1) MX382140B (enExample)
MY (1) MY173804A (enExample)
NZ (1) NZ718153A (enExample)
PH (1) PH12016500371A1 (enExample)
PL (1) PL3038633T3 (enExample)
PT (1) PT3038633T (enExample)
RS (1) RS61347B1 (enExample)
RU (1) RU2733897C2 (enExample)
SA (1) SA516370622B1 (enExample)
SG (1) SG11201602679VA (enExample)
SI (1) SI3038633T1 (enExample)
SM (1) SMT202100006T1 (enExample)
UA (1) UA117933C2 (enExample)
WO (1) WO2015028558A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102149028B1 (ko) * 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
US9982022B2 (en) * 2013-08-28 2018-05-29 Affibody Ab Binding polypeptides having a mutated scaffold
WO2015028558A1 (en) * 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
IL307197B2 (en) 2017-07-11 2026-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
WO2022171892A1 (en) * 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
EP4426348A4 (en) * 2021-11-01 2025-10-01 Ipc Res Llc ADMINISTRATION OF C5-BINDING PROTEINS
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
ES2373832T3 (es) * 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
BR112013000452A2 (pt) 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
JP6577868B2 (ja) 2012-12-19 2019-09-18 アフィボディ・アーベー 新規ポリペプチド
US9982022B2 (en) * 2013-08-28 2018-05-29 Affibody Ab Binding polypeptides having a mutated scaffold
WO2015028558A1 (en) * 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5

Also Published As

Publication number Publication date
EP3811961B1 (en) 2025-08-20
CN105658228A (zh) 2016-06-08
CA2926976A1 (en) 2015-03-05
HRP20210013T1 (hr) 2021-04-02
RU2733897C2 (ru) 2020-10-09
SMT202100006T1 (it) 2021-03-15
SI3038633T1 (sl) 2021-05-31
DK3038633T3 (da) 2021-01-11
MY173804A (en) 2020-02-24
PL3038633T3 (pl) 2021-07-19
RU2016111115A (ru) 2017-10-03
ES2842105T3 (es) 2021-07-12
KR102446636B1 (ko) 2022-09-23
RS61347B1 (sr) 2021-02-26
SA516370622B1 (ar) 2018-12-23
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
EP3811961A1 (en) 2021-04-28
CN105658228B (zh) 2020-02-07
WO2015028558A1 (en) 2015-03-05
LT3038633T (lt) 2021-03-25
RU2016111115A3 (enExample) 2018-04-25
SG11201602679VA (en) 2016-05-30
US20160311870A1 (en) 2016-10-27
EP3038633B1 (en) 2020-10-14
AU2014314222A1 (en) 2016-04-21
IL244218A0 (en) 2016-04-21
PH12016500371B1 (en) 2016-05-02
KR20160048121A (ko) 2016-05-03
NZ718153A (en) 2022-05-27
JP6767865B2 (ja) 2020-10-14
JP2016529270A (ja) 2016-09-23
PH12016500371A1 (en) 2016-05-02
HUE052613T2 (hu) 2021-05-28
MX2016002397A (es) 2016-09-08
HK1225656A1 (en) 2017-09-15
JP2020172505A (ja) 2020-10-22
US9994626B2 (en) 2018-06-12
BR122023020080A2 (pt) 2023-12-26
CY1123732T1 (el) 2021-10-29
MX382140B (es) 2025-03-13
IL244218A (en) 2017-11-30
UA117933C2 (uk) 2018-10-25
PT3038633T (pt) 2021-01-14
RU2020128977A (ru) 2021-11-30
EP3038633A1 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
EP3811961B1 (en) Stable polypeptides binding to human complement c5
JP5827994B2 (ja) ポリペプチド
JP6590695B2 (ja) アルブミン結合ポリペプチド
KR102345999B1 (ko) Il-1 베타 결합성분
CN116987154A (zh) 具有突变的支架的结合多肽
BR112020018563A2 (pt) Anticorpos de domínio único que se ligam à neurotoxina do tétano
HK40050539B (en) Stable polypeptides binding to human complement c5
HK40050539A (en) Stable polypeptides binding to human complement c5
KR20230035079A (ko) 응고인자 xi(fxi) 결합 단백질
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
CN113880949A (zh) 凝血因子xi(fxi)结合蛋白
AU2023357539A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
HK1225656B (en) Stable polypeptides binding to human complement c5
CN116262784A (zh) 增强FcRn亲和力的Fc变体
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano
CN113880950A (zh) 凝血因子xi(fxi)结合蛋白
EP4545554A1 (en) A recombinant polypeptide comprising a metal-binding motif
KR20200033807A (ko) 전압-게이팅된 칼슘 채널 보조 서브유닛 α2δ 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190821

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826